


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (original): A medicine for the prevention or treatment of urinary frequency or incontinence, which comprises combination of a phenoxyacetic acid derivative represented by a general formula:



wherein R1 represents a hydroxy group or a lower alkoxy group, or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof and an α_1 -adrenoceptor blocker.

2. (original): A medicine as claimed in claim 1 wherein the phenoxyacetic acid derivative represented by the general formula (I) is ethyl (-)-2-[4-[2-[(1S, 2R)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl]-2,5-dimethoxyacetate.

3. (original): A medicine as claimed in claim 1 or 2 wherein the α_1 adrenoceptor blocker is silodosin, tamsulosin, prazosin, terazosin or naftopidil, or pharmaceutically acceptable salt thereof.

4. (original): A medicine as claimed in claim 3 wherein the α_1 adrenoceptor blocker is silodosin or tamsulosin, or a pharmaceutically acceptable salt thereof.

5. (original): A medicine as claimed in claim 3 wherein the dosage of prazosin or a pharmaceutically acceptable salt thereof is 1 to 12 mg/day as oral dose of prazosin hydrochloride for an adult human.

6. (original): A medicine as claimed in claim 3 wherein the dosage of naftopidil or a pharmaceutically acceptable salt thereof is 25 to 150 mg/day as oral dose of naftopidil for an adult human.

7. (original): A medicine as claimed in claim 4 wherein the dosage of silodosin or a pharmaceutically acceptable salt thereof is 1 to 16 mg/day as oral dose of silodosin for an adult human.

8. (original): A medicine as claimed in claim 4 wherein the dosage of tamsulosin or a pharmaceutically acceptable salt thereof is 0.1 to 0.8 mg/day as oral dose of tamsulosin hydrochloride for an adult human.

9. (currently amended): A combination formulation for the prevention or treatment of urinary frequency or incontinence, which comprises a phenoxyacetic acid derivative

represented by the general formula (I) as claimed in claim 1 or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof and an $\alpha 1$ -adrenoceptor blocker.

10. (currently amended): An enhancing agent of an efficacy of a phenoxyacetic acid derivative represented by the general formula (I) as claimed in claim 1 or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof for the prevention or treatment of urinary frequency or incontinence, which comprises as an active ingredient an $\alpha 1$ -adrenoceptor blocker.

11. (currently amended): A method for the prevention or treatment of urinary frequency or incontinence, characterized by using a phenoxyacetic acid derivative represented by the general formula (I) as claimed in claim 1 or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof in combination with an $\alpha 1$ -adrenoceptor blocker.